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514Objective:We sought to evaluate the effect of tumor size, location, and clinical nodal status on outcomes after
thoracoscopic lobectomy for lung cancer.
Methods: All patients who underwent attempted thoracoscopic lobectomy for lung cancer between June 1999
and October 2010 at a single institution were reviewed. A model for morbidity including published risk factors
as well as tumor size, location, and clinical N status was developed by multivariable logistic regression.
Results: During the study period, 916 thoracoscopic lobectomies met study criteria: 329 for peripheral, clinical
N0 tumors3 cm and 504 for tumors that were central, clinical node positive, or>3 cm. Tumor location could not
be documented for 83 patients. Conversions to thoracotomy occurred in 36 patients (4%); patients with clinically
node-positive disease had higher conversion rates (11 conversions in 153 clinical N1 to N3 patients [7.2%] vs 25
in 763 clinicalN0 patients [3.3%,P¼ .03].Overall operativemortalitywas 1.6% (14 patients) andmorbiditywas
32% (296 patients). Although patients with larger tumors (P¼ .006) and central tumors (P¼ .01) had increased
complications by univariate analysis, tumor size>3 cm (P ¼ .17) and central location (P ¼ .5) did not predict
significantly overall morbidity in multivariate analysis. Clinical node status did not predict increased complica-
tions by univariate or multivariate analysis. Significant predictors of morbidity in multivariable analysis were in-
creasing age, decreasing forced expiratory volume in 1 second, prior chemotherapy, and congestive heart failure.
Conclusions: Thoracoscopic lobectomy for lung cancers that are central, clinically node positive, or>3 cm does
not confer increased morbidity compared with peripheral, clinical N0 cancers that are<3 cm. (J Thorac Cardi-
ovasc Surg 2013;145:514-21)Earn CME credits at
http://cme.ctsnetjournals.org
A thoracoscopic approach to lobectomy has less morbidity
compared with thoracotomy and has been advocated to be
the gold standard resection approach for early-stage non–
small cell lung cancer (NSCLC).1-6 The feasibility of
performing a thoracoscopic lobectomy for lung nodules
<3 cm suspected to be NSCLC was demonstrated by
a prospective, multi-institution trial.7 Although thoraco-
scopic techniques for more advanced tumors and resections
have been reported, there is a lack of literature on the impact
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The Journal of Thoracic and Cardiovascular Surgand higher stage tumors.8-12 This study was performed to
evaluate the effect of tumor size, location, and clinical
nodal status on outcomes after thoracoscopic lobectomy
for NSCLC. The purpose of the study was to test the
hypothesis that performing a thoracoscopic lobectomy for
tumors that are>3 cm, have a central location, or have
clinically positive lymph nodes does not have increased
perioperative morbidity compared with thoracoscopic
lobectomy for peripheral tumors that are<3 cm and have
clinically negative nodes.
METHODS
After local institutional review board approval was granted, the Duke
University Medical Center Data Center was queried for Current Procedural
Terminology codes linked with pulmonary resection by a thoracoscopic ap-
proach between June 1999 and October 2010. Careful attention was paid to
individual operative notes and surgical pathology reports to identify all pa-
tients who underwent anatomic lobectomy via thoracoscopy for primary
lung cancer. Patients who had attempted lobectomy via thoracoscopy but
had conversions to thoracotomy for any reasonwere included in the thoraco-
scopic group for the analysis. Patients who had resection of>1 lobe or who
underwent concomitant chest wall resection were excluded from the study.
Retrospective review of an institutional, prospective database main-
tained on all thoracic surgery patients was performed. Data collected in-
cluded demographics, preoperative functional status, the use of induction
therapy, smoking history, significant comorbidities, the histology and stage
of disease, intraoperative details, and postoperative course. Chart review
was used as necessary to complete data collection. Any postoperative event
prolonging or otherwise altering the postoperative course was recorded
along with all operative deaths, which were defined as deaths that occurredery c February 2013
Abbreviations and Acronyms
FEV1 ¼ forced expiratory volume in 1 second
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
VATS ¼ video-assisted thorascopic surgery
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same hospitalization. Deaths were captured both by chart review and use
of the Social Security Death Index Database. The definitions of postoper-
ative events were based onversion 2.08 of the Society of Thoracic Surgeons
General Thoracic Surgery Database.13 Morbidity was defined as the occur-
rence of at least 1 of these postoperative events. This composite end point
definition was chosen because all events can cause patient discomfort, re-
quire additional testing and treatment, lead to longer hospital stays, and in-
crease overall costs, and thus are all clinically significant.
The recorded tumor size was that of the largest nodule in cases in which
>1 nodule was present. Tumor location definition was based on location of
tumor relative to branching lobar bronchi and blood vessels. A tumor was
classified as central if removal would require division of lobar structures
that would render any remaining lobar lung tissue nonfunctional. Tumors
that could be removed via wedge resection while leaving remaining func-
tional lobar lung tissue were classified as peripheral. Therefore, tumors for
which a wedge resection could be performed to establish diagnosis prior to
completion lobectomywere classified as peripheral. Tumors for which a di-
agnosis had not been established prior to resection but were considered not
to be amenable to wedge at the time of resection by the operating surgeon
were classified as central. Preresection imaging for all other patients was
reviewed by an attending thoracic surgeon (M.F.B.), and was classified
as central/peripheral based on the previous criteria.
In cases when clinical N stagewas not recorded explicitly prior to resec-
tion, pretreatment imaging was reviewed to establish the clinical N stage.
Nodes were considered clinically positive if an official positron emission
tomography (PET) report described the presence of nodal activity suspi-
cious for metastatic disease. The actual values for the standardized update
ratio were not provided routinely in PET scans at our institution. For pa-
tients who had computed tomographic scans but not PET scans, patients
were considered clinically N positive if the official radiology report de-
scribed abnormally enlarged lymph nodes>1 cm in the short axis. When
patients had both computed tomographic and PET scans, the PET result
was used to determine clinical stage.
Thoracoscopic lobectomywas performedwithout any rib spreadingwith
the thoracoscope placed in the 8th intercostal space in the midaxillary line
and a 4 to 5-cm anterior utility incision in the 5th intercostal space.14 An
epidural catheter for postoperative pain relief was offered routinely to all
patients regardless of planned operative approach. Chest tubes were placed
routinely on water seal immediately postoperatively and were removed
when no air leak was present and drainage over 24 hours was<200 mL.
Univariate analyses were performed relating operative morbidity to the
following patient characteristics: age, tumor size (3 cm vs>3 cm), tumor
location (central vs peripheral), clinical N stage (N0 vs N1-N3), the pres-
ence of diabetes mellitus, the presence of renal insufficiency, history of
prior chemotherapy, history of prior radiation, a history of smoking, history
of congestive heart failure, history of coronary artery disease, previous tho-
racic surgery, and preoperative pulmonary function tests (forced expiratory
volume in 1 second [FEV1] and diffusion capacity of the lung to carbon
monoxide). Tumor size was analyzed as classified as noted earlier and
not according to T stage to account for tumors in which T stage was up-
staged as a result of the presence of additional nodules in the lobe or pleural
involvement. The variables that were significant at P<.20 were entered
into a multivariable logistic regression with morbidity as the dependent
variable, and significance set at the .05 level.The Journal of Thoracic and CaPropensity score analysis that created subclasses of patients with central
and peripheral tumors with similar covariate distributions was used as an
alternative method of assessing the impact of tumor location on overall
morbidity. Multivariable analysis was performed with tumor location as
the outcome and age, percent predicted FEV1, percent predicted diffusion
capacity of the lung to carbon monoxide, tumor size (3 cm vs>3 cm),
clinical N stage (N0 vs N1-N3), a history of smoking, history of coronary
artery disease, previous thoracic surgery, and history of prior chemotherapy
as potential predictors. Propensity scores were calculated using a logistic
regression model that was created using stepwise variable selection with
a P value of .2 for entry into the model and a P value of .05 to stay in
the model. Only patients with propensity scores between 0.40 and 0.60
were then included in subsequent analysis in which baseline characteristics
and outcomes were compared based on tumor location.
Unpaired Student t tests were used to compare continuous data, Fisher
exact tests for dichotomous data, and c2 for categorical variables. A
2-tailed P value of<.05 was considered significant. Data are presented
as mean  standard error of the mean unless otherwise noted. The SAS
9.0 statistical package (SAS Institute, Cary, NC) was used for statistical
analyses.RESULTS
Of 1195 thoracoscopic lobectomies performed during the
study period, 916 met the study criteria. Overall, 620 (68%)
lobectomies were for tumors 3 cm in size (median, 2 cm)
and 296 (32%) lobectomies were for tumors>3 cm in size
(median, 4.3 cm). Most patients (n ¼ 763, 83%) were clin-
ical stage N0, whereas 153 (17%) were clinical stage N1 to
N3. Of the patients with tumors>3 cm, 213 patients had
tumors between 3.1 cm and 5 cm, 60 between 5.1 cm and
7 cm, and 23>7 cm. Tumor location could not be docu-
mented for 83 patients. Of 833 patients with documented
tumor location, 487 tumors (58%) were peripheral and
346 (42%) were central.
The number of thoracoscopic lobectomies per year, both
overall and stratified by peripheral T1AN0 versus other, is
depicted inFigure 1.Overall, 329patients (39%) had periph-
eral, clinical N0 tumors 3 cm and 504 patients (61%) had
tumors that were>3 cm, central, or clinical node positive.
The percentage of procedures performed for larger tumors,
central tumors, and clinically positive nodal disease all
trended upward throughout the course of the study period
(Figure 2). Over the same time frame, 541 lobectomies via
thoracotomy (89 sleeve resections) were performed. The
pathologic stagedistributionof the thoracotomy lobectomies
was 73 patients stage IA (13%), 109 patients stage IB
(20%), 119 patients stage IIA (22%), 76 patients stage IIB
(14%), 140 patients stage IIIA (26%), 11 patients stage
IIIB (2%), and 11 patients stage IV (2%).
Demographic, baseline characteristics, and comorbid
conditions are shown in Table 1. Compared with patients
with tumors that were peripheral,<3 cm, and had clinically
negative nodes, patients with central tumors, tumors>3 cm,
or clinically positive nodes had worse pulmonary function
and were more likely to have had coronary artery disease,
previous thoracic surgery, and induction chemotherapy.
The ages of these 2 groups were not significantly different,rdiovascular Surgery c Volume 145, Number 2 515
FIGURE 2. A-C, Percentage of thoracoscopic lobectomy performed in
each year of the study for tumors>3 cm (A), tumors with clinically positive
nodal disease (B), and tumors in a central location (C).
FIGURE 1. Distribution of thoracoscopic lobectomy for smaller and
larger tumors per study year. (Note: The year 1999 only included 7 months
for analysis; 2010 only included 10 months for analysis.)
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prior radiation, congestive heart failure, and renal insuffi-
ciency were also not significantly different.
Outcomes are summarized in Table 1. Overall operative
mortality was 1.6% (14 patients) and morbidity was 32%
(296 patients). The median chest tube duration for all pa-
tients was 3 days; the median hospitalization was 4 days.
The most common postoperative events were atrial arrhyth-
mia (n¼ 128, 14%), air leak>5 days (n¼ 107, 12%), post-
operative bronchoscopy (n ¼ 54, 6%), and postoperative
transfusion (n¼ 47, 5%). Table 1 also shows the final path-
ologic stage for the patients in the study. As expected, pa-
tients with smaller, peripheral, clinically node-negative
tumors were much more likely to be pathologic stage I
than patients with larger, central, or clinically node-
positive tumors. Of the 763 patients who had clinically
node-negative tumors, 98 patients (13%) were upstaged to
pathologicN1 (10%, n¼ 77) or pathologicN2 (3%, n¼ 21).
In univariate analysis, patients with central tumors, tu-
mors>3 cm, or clinically positive nodes had increased over-
all morbidity, as well as increased rates of prolonged air
leaks, postoperative bronchoscopy, postoperative transfu-
sion, and reintubation compared with the patients with tu-
mors that were peripheral, <3 cm, and had clinically
negative nodes. However, multivariate analysis did not
demonstrate tumor size, location, or nodal status to be sig-
nificant risk factors for overall morbidity (Table 2). Al-
though patients with larger tumors (P ¼ .006) and central
tumors (P¼ .01) had increased complications by univariate
analysis, tumor size>3 cm (P ¼ .17) and central location
(P ¼ .5) did not predict overall morbidity significantly in
multivariate analysis. Clinical node status did not predict in-
creased complications by univariate or multivariate analy-
sis. The significant predictors of morbidity by
multivariable analysis were age, FEV1 prior chemotherapy,
and congestive heart failure.
Propensity score analysis identified 135 patientswith cen-
tral tumors and 122 patients with peripheral tumors with
similar baseline characteristics (Table 3). There were no516 The Journal of Thoracic and Cardiovascular Surgstatistically significant differences in perioperative mortal-
ity, overall morbidity, or hospital stay between the patients
with central tumors and the patients with peripheral tumors.
These results are consistent with the previously described
multivariate analysis results that show central location
does not predict increased overall morbidity independently.
Other stratifications of tumor size were also evaluated to
assess the impact of tumor size on outcomes. The difference
between morbidity of patients with tumors>5 cm (40%, 33
of 83 patients) and patients with tumors<5 cm (32%, 263
of 833) was not statistically significant (P ¼ .1). Morbidity
stratified by more discrete size subgroups were as follows:
29% (182 of 620 patients) for tumors<3 cm, 38% (81 of
213 patients) for tumors between 3 cm and 5 cm, 43%
(26 of 60 patients) for tumors between 5 cm and 7 cm,
and 30% (7 of 23 patients) for tumors>7 cm.ery c February 2013
TABLE 1. Demographics and perioperative outcomes for all patients and stratified by tumor size, location, and clinical N status
All patients
(n ¼ 916)
Peripheral, 3 cm, and
clinical N0 (n ¼ 329)
Central,>3 cm, or clinical
N1-N3 (n ¼ 504) P value*
Baseline characteristics
Median age, y (range) 67 (21-93) 67 (38-88) 68 (21-93) .2
% Predicted forced expiratory volume in 1 second,% 74  20 78  21 72  20 <.0001
% Predicted diffusion capacity to carbon monoxide 77  21 82  21 75  21 <.0001
Smoking history, n (%) 792 (86) 274 (83) 444 (88) .051
Coronary artery disease, n (%) 196 (21) 61 (18) 125 (25) .04
Diabetes, n (%) 150 (16) 60 (18) 80 (16) .4
Previous thoracic surgery, n (%) 144 (16) 39 (12) 92 (18) .01
Prior chemotherapy, n (%) 60 (6) 9 (3) 48 (10) .0001
Prior radiation, n (%) 48 (5) 14 (4) 31 (6) .3
Congestive heart failure, n (%) 43 (5) 18 (5) 22 (4) .4
Renal insufficiency, n (%) 41 (4) 13 (4) 26 (5) .5
Outcomes
Perioperative mortality, n (%) 14 (1.6) 4 (1.2) 8 (1.6) .8
Conversion, n (%) 36 (4) 11 (3) 23 (5) .5
Hospital stay, Days 4.9  4.3 4.4  3.7 5.3  4.8 .005
Hospital stay>14 d, n (%) 25 (3) 6 (2) 19 (4) .15
Overall morbidity, n (%) 296 (32) 85 (26) 188 (37) .0007
Pathologic stage, n (%) <.0001
Stage I 634 (69) 280 (85) 296 (59)
Stage II-IV 282 (31) 49 (15) 208 (41)
Atrial fibrillation, n (%) 128 (14) 41 (12) 76 (15) .3
Prolonged air leak>5 d, n (%) 107 (12) 28 (9) 70 (14) .02
Need for postoperative bronchoscopy, n (%) 54 (6) 9 (3) 44 (9) .0004
Postoperative transfusion, n (%) 47 (5) 12 (4) 34 (7) .06
Pneumonia, n (%) 30 (3) 8 (2) 21 (4.2) .2
Need for new chest tube, n (%) 22 (2) 5 (2) 16 (3) .2
Confusion/delirium, n (%) 16 (2) 4 (1) 11 (2) .4
Reintubation, n (%) 15 (2) 1 (0.3) 14 (3) .007
Renal failure, n (%) 13 (1) 5 (2) 8 (2) 1
Myocardial infarction, n (%) 4 (0.4) 0 3 (0.6) .3
Tracheostomy, n (%) 4 (0.4) 1 (0.3) 3 (0.6) 1
Reoperation for bleeding, n (%) 3 (0.3) 0 3 (0.6) .3
Empyema 3 (0.3) 1 (0.3) 2 (0.4) 1
Data is presented as count and percentage or mean standard deviation, as appropriate. *Comparison between peripheral,3 cm, and clinical N0 vs central,>3 cm, or clinical N1
to N3.
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Conversion was achieved by enlarging the anterior utility in-
cision in 19 patients and performing a posterolateral thora-
cotomy in 15 patients; the conversion method wasn’t
specified in 2 patients. Conversion indication was bleeding
in 21 patients (pulmonary artery branch, n¼ 16; unspecified
location, n ¼ 2; pulmonary vein, n ¼ 1; bronchial vessel,
n ¼ 1; and lung parenchyma, n ¼ 1) and difficult dissec-
tion/hilar adenopathy in 9 patients. In addition, conversions
were made in 1 patient for each of the following reasons: in-
ability to locate nodule, pulmonary artery invasion, need to
perform pulmonary arterioplasty after lobectomy resulted
in stenosis, inability tomaneuver the lung, failure to progress,
and failure to obtain adequate lung isolation.Noneof the con-
versions resulted in intraoperativedeath, and thedifference in
perioperative mortality between patients that required con-
version and patients without conversion was not statisticallyThe Journal of Thoracic and Casignificant (5.6% [2 of 36 patients] vs 1.4% [12 of 880
patients], P ¼ .1). Patients who required conversion did
have significantly higher overall morbidity compared with
patients without conversion (61% [22 of 36 patients] vs
31% [274 of 880 patients], P¼ .0004). The individual com-
plication that was significantly higher in the converted pa-
tients was postoperative transfusion (25% [9 of 36
patients] vs 4% [38 of 880 patients],P<.0001). The conver-
sion rate was not higher for tumors>3 cm (12 conversions in
296 patients [4%] with tumors>3 cm vs 24 conversions in
620patients [3.9%]with tumors<3 cm,P¼ .7) or for central
tumors (17 conversions in 346 patients [4.9%] with central
tumors vs 17 conversions in 487 patients [3.5%] with periph-
eral tumors, P ¼ .3). The conversion rate was increased for
patientswith clinically node-positive disease (11 conversions
in 153 clinical N1-N3 patients [7.2%] vs 25 conversions in
763 clinical N0 patients [3.3%], P ¼ .03).rdiovascular Surgery c Volume 145, Number 2 517
TABLE 2. Multivariate risk model for complications
Variable
Univariate
P value
Multivariate analysis
Odds
ratio
95%
Confidence
interval
P
value
Age per 1-year increase <.0001 1.06 1.04-1.08 <.0001
% Predicted forced expiratory
volume in 1 second per 1%
increase
<.0001 0.98 0.97-0.99 <.0001
Prior chemotherapy .02 2.40 1.14-5.08 .02
Congestive heart failure .003 2.16 1.03-4.54 .04
% Predicted diffusion capacity
to carbon monoxide per 1%
decrease
<.0001 .1
Tumor size>3 cm vs 3 cm .006 .17
Tumor location (central vs
peripheral)
.01 .5
Previous thoracic surgery .009 .5
Smoking history .04 .6
Coronary artery disease .004 .8
Prior radiation therapy .16 1
Diabetes .4
Clinical N stage (N1-N3 vs N0) .5
Renal insufficiency .6
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Thoracoscopic lobectomy was first reported in the 1990s
and, since then, several studies have shown advantages to
this technique over thoracotomy. These advantages includeTABLE 3. Baseline characteristics and outcomes for centrally and
peripheral located tumors after propensity scoring used to create
subclasses of patients with similar baseline characteristic distributions
Central
tumors
(n ¼ 135)
Peripheral
tumors
(n ¼ 122)
P
value
Baseline characteristics
Age, years 67.5  8.6 67.5  9.3 1
% Predicted forced expiratory
volume in 1 second
68  21 70  22 .5
% Predicted diffusion capacity to
carbon monoxide
72  22 72  18 .9
History of smoking, (%) 124 (92) 107 (88) .3
Coronary artery disease, (%) 40 (30) 23 (19) .06
Previous thoracic surgery, (%) 17 (13) 19 (16) .6
Prior chemotherapy, (%) 11 (8) 6 (5) .4
Tumor size, (%) .2
3 cm 40 (30) 46 (38)
>3 cm 95 (70) 76 (62)
Clinical nodal status, (%) .3
Clinical N0 102 (76) 99 (81)
Clinical N1-N3 33 (24) 23 (19)
Outcome variables
Perioperative mortality, (%) 3 (2.2) 2 (1.6) 1
Overall morbidity, (%) 56 (41) 44 (36) .4
Hospital stay, days 5.3  3.6 5.8  6.7 .4
Data is presented as count and percentage ormean standard deviation, as appropriate.
518 The Journal of Thoracic and Cardiovascular Surgless pain, better pulmonary function, shorter hospitaliza-
tion, decreased overall costs, and fewer overall complica-
tions.1-5,14-21 Despite these demonstrated advantages,
a thoracoscopic approach was used in less than 45% of
lobectomies as recently as 2010.22
The relatively limited application of thoracoscopic lobec-
tomy is likely multifactorial, including surgeon training, ex-
perience, preferences, and biases. Concerns regarding
safety, completeness of oncologic resection, and technical
difficulties may also have prevented more widespread use
of the thoracoscopic technique. Indeed, increased T and N
stages, hilar adenopathy, previous thoracic radiation, and
induction therapy were all considered contraindications to
thoracoscopic lobectomy even in the mid 2000s.23 The pro-
spective multicenter trial that was performed to evaluate the
feasibility of this technique limited inclusion to patients
with small, peripheral, clinical stage 1A tumors.7 However,
thoracoscopic lobectomy has been associated with im-
proved compliance to adjuvant chemotherapy compared
with thoracotomy.24,25 Considering the importance of
multimodality therapy to survival of advanced-stage lung
cancer, investigation into the use of thoracoscopic lobec-
tomy in these cases is warranted.
The purpose of the current study was to analyze the im-
pact of tumor size, location, and clinical N stage on out-
comes after thoracoscopic lobectomy for lung cancer. In
this study, overall operative mortality and morbidity was
comparable with reported outcomes for thoracoscopic lo-
bectomy in the Society of Thoracic Surgeons database.2 A
high proportion of patients (55%) had tumors that were
either >3 cm in size, central, or clinical node positive.
None of these characteristics was associated with increased
postoperative complications by multivariate analysis. The
factors that were significant predictors of morbidity in mul-
tivariable analysis were increasing age, decreasing FEV1,
prior chemotherapy, and congestive heart failure. Our re-
sults demonstrate that thoracoscopic lobectomy is safe
and feasible for lung cancers that are central, clinically
node positive, or>3 cm in size.
Other recent studies have also shown the safety of thora-
coscopic lobectomy in locally advanced lung cancer, in-
cluding a retrospective review of 114 patients who
underwent lobectomy for advanced clinical stage NSCLC
between January 1, 2002, and July 31, 2007.8 Advanced
clinical stage NSCLC was defined as tumors 4 cm, T3
or T4 (based on the American Joint Committee on Cancer,
6th edition), and/or tumors that received neoadjuvant che-
motherapy. Thoracoscopic lobectomy was attempted in
95 patients and completed in 73 patients. Conversion to tho-
racotomy was necessary in 22 patients (23%). Muscle-
sparing thoracotomy was the procedure of choice in 19
patients. Length of stay and major postoperative complica-
tions were similar between the thoracoscopy group and the
open group. A significantly higher percentage of patientsery c February 2013
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group compared with the open group (37.2% for thoraco-
scopy vs 5.3% for open, P ¼ .006). The thoracoscopic
and open groups did not differ significantly in overall sur-
vival or disease-free survival. The authors concluded that
thoracoscopic lobectomy for advanced lung cancer can be
performed safely with an acceptable mortality rate, al-
though with a higher conversion rate than thoracoscopic
lobectomy for early-stage NSCLC.
Kim and colleagues [9] analyzed the outcomes of unex-
pected pathologic N1 and N2 disease after thoracoscopic lo-
bectomy for clinical stage I NSCLC. Themedical records of
89 patients were reviewed retrospectively to assess clinical
characteristics, early postoperative complications, recur-
rence patterns, and survival. Complications occurred in 16
patients (18%). For patients with N1 disease, overall sur-
vival was 98% at 1 year and 98% at 3 years. For patients
with N2 disease, overall survival was 98% at 1 year and
89% at 3 years. The authors concluded that survival after
thoracoscopic lobectomy for patients with pathologic N1
or N2 diseasewas comparablewith survival after lobectomy
through a thoracotomy. However, clinicians must continue
to collect and evaluate long-term follow-up data in larger
numbers of patients to ensure that a thoracoscopic approach
does not compromise oncologic efficacy.
The conversion rate to thoracotomy in the current study
was 4%, which is relatively low in comparison with other
series.1,7-9,14 The conversion rate was not higher for
tumors>3 cm or for central tumors. Similarly, Hennon
and associates8 did not find an association between larger
tumors and need for conversion. The conversion rate was in-
creased for patients with clinically node-positive disease,
which is likely as result of the fact that involvement of hilar
nodes can increase the difficulty of dissection around the
pulmonary hilar structures. In this study, conversion to tho-
racotomy did not increase mortality but did result in in-
creased morbidity, primarily because of an increased rate
or postoperative transfusion. When planning a thoraco-
scopic approach in the setting of clinically positive nodes,
surgeons should consider discussing with the patient preop-
eratively the potentially higher chance of conversion. In ad-
dition, surgeons may also wish to have a lower threshold to
conversion in this setting, especially when they are early in
their thoracoscopic lobectomy experience.
As the experience with thoracoscopic lobectomy has
grown, thoracoscopy is now used for potentially challeng-
ing technical situations such as previous thoracic surgery
and following induction therapy. In addition, the thoraco-
scopic approach is currently applied to more complex resec-
tions, including chest wall resection, sleeve lobectomy, and
pneumonectomy.10-12 It appears that in experienced centers,
these procedures are performed with acceptable morbidity
and mortality. As the application of thoracoscopy expands
to more complex situations, it is important to determineThe Journal of Thoracic and Carisk factors for potential complications to maximize
patient safety. A major strength of this study is that it
includes a large number of patients, allowing the creation
of a model for morbidity that incorporates multiple
clinical variables to elucidate those factors.
The main limitation of this study is the retrospective na-
ture and the selection bias in which patients were chosen for
a thoracoscopic approach, particularly early in experience.
However, approximately 20% of patients who underwent
a thoracoscopic approach in recent years have had clinically
positive nodes. This shift in distribution reflects a general
institutional practice of performing thoracoscopic explora-
tion in most patients, even when a thoracotomy is consid-
ered likely based on expected difficulty with hilar
exposure and dissection as a result of tumor size or location.
Thoracoscopic exploration may identify unexpected meta-
static disease or another indicator of ‘‘unresectability’’
and may spare the patient a thoracotomy, which likely
will allow the patient to begin other needed systemic ther-
apy more quickly.
The positive effects of approach on outcome in this study
also cannot necessarily be generalized immediately to all
thoracic surgeons, considering the extensive experience of
surgeons at our institution with thoracoscopic lobectomy.
In particular, the majority of tumors in this study were<3
cm, and only 9% (n ¼ 83) were>5 cm. Surgeons may
not want to attempt a thoracoscopic approach for tumors
>3 cm until they feel completely comfortable with a thora-
coscopic approach for smaller tumors. The decision of if
and when to convert to thoracotomy should also be based
on the surgeon’s overall experience with a thoracoscopic
approach, and less-experienced thoracoscopic surgeons
should likely have a lower threshold for conversion when
dissection is difficult. However, surgeons who become com-
fortable with thoracoscopic lobectomy can likely achieve
similar results to those shown in this series and should con-
sider this approach preferentially for lung cancer in all pa-
tients, even for larger tumors and in the presence of
adhesions from previous surgery or higher cancer stages.References
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Dr Joseph Shrager (Stanford, Calif). I appreciate the opportu-
nity to discuss. Mark, very nice paper from what is obviously one
of the most experienced video-assisted thorascopic surgery
(VATS) lobectomy centers and I will not resist the opportunity
to remind you that I am probably—. I think I am the first person
who ever took you through a lobectomy when you were a PGY4
at Penn. Is that right?
Dr Berry. That is right. At Pennsylvania Hospital.520 The Journal of Thoracic and Cardiovascular SurgDr Shrager. So I take pride there.
Moderator. Watch out. That means he’s about to get you.
[laughter]
Dr Shrager. I think it is only natural as you gain more experi-
ence with a newer procedure like VATS lobectomy that unless you
feel there is a compelling reason not to take on tougher tumors that
is what you are going to do. I think you have shown very nicely
with these data that, in your hands at least, in the hands of the
most experienced place in the country, moving to these more chal-
lenging tumors does not increase morbidity and mortality in any
major way anyway, so it is doable if you are very experienced.
The more important question I think is not answered here and
that is: Is there an oncologic reason not to tackle these tumors?
In other words, should we be doing this? I think every survival
analysis that is really scientifically done, published for VATS lo-
bectomy, is focused on stage I tumors, so we do not have any
data yet about survival for stage II and stage III tumors that are
done thoracoscopically and that is what we would need to see to
really answer that second question. My personal bias is that
when we do VATS lobectomies we tend to fragment lymph nodes,
leave little pieces of it stuck to the bronchus—where we would
normally get it out if we were open—and just do, generally,
a less clean job. That is not a problem in cases that eventually prove
to be N0, but I feel very bad when I have done a VATS lobectomy
and the case ends up being N1 or N2. I feel like I have done the
patient a disservice because I might have left a little tiny piece
of something. My hunch is that when we get larger series we are
going to be able to show reduced survival for N1 and N2. So,
my first question is: What is your gut feeling about that statement
that clearance is not quite as good and that might lead to less sur-
vival in the long term?
Dr Berry.Well, I do agree that when you are dissecting the no-
des out thoracoscopically you usually fragment them more than
when you are doing an open procedure, particularly when you
are doing your mediastinal lymph node dissection in level 7 or
4R. My personal feeling is that as long as you are persistent at
clearing out everything that you see, you can do just as good of
a job. We have not looked at the survival of the patients in the
study. We have looked at the survival after thoracoscopic lobec-
tomy and compared it with thoracotomy. We have not published
those results, but the preliminary investigation suggests that the
outcomes are either the same or maybe better after VATS lobec-
tomy. The reason we really have not tried to publish those yet is
we are still trying to make sure that we really do a good job of strat-
ifying the patients and making sure they are matched well because
there really should not be that much of a difference in the long term
between VATS and a thoracotomy approach.
We have had a few papers published by our radiation oncology
colleagues at Duke who have developed models looking at local
recurrences as well as distant failures, and one of the variables
that they have included is a VATS approach. They have never
found that a VATS approach predicts worse outcomes.
Dr Shrager. I suspect that it is so rare that the little fragment of
node you leave behind actually is the malignant fragment that it
would take a huge study to show it. Maybe it really does not matter.
Second question: Do you have information on exactly what
were the causes of conversion to thoracotomy? If they were
done to ensure clearance of nodes in cases when you could notery c February 2013
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Sget the nodes off an important structure, that would be appropriate
and expected, but if they were for bleeding, which is suggested, re-
ally, by the fact that you have increased transfusions in the patients
who were converted, that would be more concerning. Although
you did not show any increased deaths in that group, I am worried
that in less-experienced hands you might have some patients die
from intraoperative hemorrhage.
Dr Berry. I do not know the exact numbers for these patients,
but in previous studies that we have done, probably about half
the conversions are done for bleeding. It can be hard to recreate
the situation retrospectively because most of the time the op
note will be pretty bland in saying bleeding was encountered, so
we converted to thoracotomy. My personal experience with cases
that require conversion as a result of bleeding is that you can con-
trol things pretty well and you can convert and take care of prob-
lems in a very controlled fashion. Most bleeding is from
pulmonary artery branches, which are low pressure and can typi-
cally be controlled with gentle pressure. I think about half the cases
were for bleeding and probably about half the cases were just could
not expose the structures that we wanted to expose or there was
something else that required getting in and being able to palpate
to determine whether something was resectable.
Dr Shrager. Last quick question. Clinically node-positive pa-
tients had double the conversion rate and an increased transfusion
rate. You came short of saying we should not do clinically node-
positive patients.
Dr Berry. I think that if somebody has clinically positive nodes
you should be prepared both to make sure that the patient is pre-
pared for a thoracotomy and, if they are a marginal candidate,
that they would really tolerate that if you think that is going to in-
crease their risk. Despite the increased risk of needing a conver-
sion, most patients who are clinically node positive were still
able to get their procedure done with the thoracoscopic approach.
I would still say that it is okay to start out thoracoscopically, but
just have in mind that there is increased risk that you could run
in to trouble, be ready for it, and just make sure that you were pre-
pared for that beforehand. Our anesthesiologists put epidurals in
all our patients regardless ofwhether it is going to be a thoracotomy
or a thoracoscopic approach. If you use epidurals selectively, then
it might be a good idea that if someone looks like they have PET-
positive nodes, have them get an epidural because there is at least
a higher chance of getting a thoracotomy.
Dr Ross Bremner (Phoenix, Ariz). Thanks very much. Great
paper. When you convert your cases, do you just extend your
4-cm axillary incision and put in a retractor or do you make
another posterolateral thoracotomy incision?
Dr Berry. Most of the cases are just extending the utility inci-
sion. It depends on at what point in the operation there is a conver-
sion. If it is the type of thing where we put the scope in, start to
work around the hilum, and realize that we are not going to be
able to do it thoracoscopically, in those patients we usually just
make a regular posterolateral thoracotomy incision.
Dr Bremner. So posterolateral thoracotomy would be your pre-
ferred approach for a complex operation.
Dr Berry. Yes.
Dr Bremner. I guess my question, then, is: Is there a way that
you could advise people who are learning how to do this procedure
regarding which cases are going to be really hard? For example, isThe Journal of Thoracic and Cathere a size criteria? As we all know, we see tumors that are 6 or 7
cm in size that are mediastinal node negative. I mean, is there a cut-
off in the size? And what about nodal status? I guess from your pa-
per here you infer that if there are clinically node-positive nodes
near the central hilum or near pulmonary arteries, we should prob-
ably just start open?
Dr Berry. Based on what we looked at, I do not think I could
just pick a criteria that would say these cases are going to require
a conversion to thoracotomy. In my experience, and based on the
data, I think the tumors that are node positive are the ones that
are going, most likely, to require a thoracotomy.We tried to stratify
tumor size and see if we could find a size that was going to predict
that you could not do it thoracoscopically and we were not able to.
There were tumors that were 9 cm that were able to be resected
thoracoscopically in the series.
Dr Bremner. If you are taking a 9-cm tumor out of a 4-cm hole,
are you losing the benefit of a VATS lobectomy?
Dr Berry. That is sometimes the hardest part of the case, and it
sometimes requires making the incision bigger, but we still are
able to do the case without any retraction at all, which we think,
ultimately, is probably the reason why people are getting benefit
from this.
Dr Bremner. Thanks very much.
Dr Gary Gelfand (Calgary, Alberta, Canada). An excellent
paper. I was just curious—Your operative times, I mean in the
2 groups<3 cm. Did you have any data on operative time? Because
at what point does increasing operative time make it not necessar-
ily the optimal economic strategy?
Dr Berry. I cannot really answer that. We do not really have
good recordings of operative times in our patient database. Cer-
tainly, the more experienced of the surgeons, their operative times
are less. Operative time also can depend on the level of resident
that is doing the case. In general, we do not use operative time
as one of the criteria to decidewhether to convert to a thoracotomy.
There were a few patients, though, where the op note specifically
said ‘‘Due to failure to progress in the operation, the procedure was
converted to thoracotomy.’’ I can’t really give much more detail on
the operative time other than that.
Dr Steven R. DeMeester (Los Angeles, Calif).Very nice paper.
Just a question. In the patients who have to get converted, do they
lose anything? In other words, have you looked at the patients who
required conversion and compared them with similar patients who
you just started out open? Either in your learning experience, or
whatever, was there a downside to trying a VATS approach in
terms of blood loss or other complications compared with going
straight to an open approach?
Dr Berry.We did not do that. My sense is that the patients who
required a conversion because of bleeding probably had a higher
transfusion rate than if you had just started straight with thoracot-
omy. I do not think that the morbidity of the conversion patients, at
least in our series, was any different than patients who had a thora-
cotomy to start with, at least of what wewould consider significant
complications. Obviously, we would like to avoid transfusions, es-
pecially in these people with lung cancer, but the complications
that they did have were not life-threatening, and most of the
time they did not prolong the patient’s hospital stay. My sense is
that they ultimately did okay, and no worse than if they just started
with a thoracotomy.rdiovascular Surgery c Volume 145, Number 2 521
